At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Tocilizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica
In Brief
A Phase 2 clinical trial evaluating Tocilizumab for Polymyalgia Rheumatica (PMR). Completed, enrolled 10 participants across 1 site.
Detailed Summary
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients with polymyalgia rheumatica (PMR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolymyalgia Rheumatica (PMR)
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedJul 2011
Primary CompletionDec 2015
Study CompletionJan 2016
TodayJul 2026
First PostedJul 18, 2011
Enrollment StartApr 1, 2011
Primary CompletionDec 1, 2015
Study CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 15.0 years ago
Interventions
Tocilizumabdrug
Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.